Vilanterol (GW642444; GW 642444X) is a novel, inhaled, long-acting β(2) agonist with inherent 24-h activity under development as a once-daily combination therapy with an inhaled corticosteroid for COPD and asthma.
信号通路
GPCR & G Protein
靶点
β2 agonist
-
-
-
-
IC50
-
-
-
-
-
体外研究
Vilanterol displayed a subnanomolar affinity for the β(2)-AR that was comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol. In cAMP functional activity studies, vilanterol demonstrated similar selectivity as salmeterol for β(2)- over β(1)-AR and β(3)-AR, but a significantly improved selectivity profile than formoterol and indacaterol. Vilanterolalso showed a level of intrinsic efficacy that was comparable to indacaterol but significantly greater than that of salmeterol.
体内研究
in vivo: The combination of FF/VI at a strength of 100/25μg significantly (p<0.001) improved wm FEV1 (173ml) and trough FEV1 (115ml) vs. placebo. Similar effects were observed with FF/VI 50/25μg. VI 25μg over 24weeks improved lung function vs. placebo significantly for wm FEV1 (103ml, p<0.001) and trough FEV1 (67ml, p=0.017).